Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Forte Biosciences, Inc. (FBRX) EBT Margin (2016 - 2020)

Forte Biosciences (FBRX) has disclosed EBT Margin for 5 consecutive years, with 360.45% as the latest value for Q1 2020.

  • On a quarterly basis, EBT Margin rose 19018267.0% to 360.45% in Q1 2020 year-over-year; TTM through Dec 2020 was 6214.29%, a 4845317.0% increase, with the full-year FY2019 number at 176430.56%, down 17616855.0% from a year prior.
  • EBT Margin was 360.45% for Q1 2020 at Forte Biosciences, up from 117588.89% in the prior quarter.
  • In the past five years, EBT Margin ranged from a high of 163955.56% in Q2 2019 to a low of 215711.11% in Q4 2018.
  • A 5-year average of 59895.75% and a median of 25500.0% in 2019 define the central range for EBT Margin.
  • Peak YoY movement for EBT Margin: tumbled -14462053bps in 2018, then soared 34272222bps in 2019.
  • Forte Biosciences' EBT Margin stood at 874.54% in 2016, then crashed by -12492bps to 108370.0% in 2017, then crashed by -99bps to 215711.11% in 2018, then skyrocketed by 45bps to 117588.89% in 2019, then soared by 100bps to 360.45% in 2020.
  • Per Business Quant, the three most recent readings for FBRX's EBT Margin are 360.45% (Q1 2020), 117588.89% (Q4 2019), and 25500.0% (Q3 2019).